Mesoblast Ltd
ASX:MSB

Watchlist Manager
Mesoblast Ltd Logo
Mesoblast Ltd
ASX:MSB
Watchlist
Price: 2.55 AUD 0.79% Market Closed
Market Cap: 2.9B AUD
Have any thoughts about
Mesoblast Ltd?
Write Note

Mesoblast Ltd
Cash Interest Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mesoblast Ltd
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Interest Paid CAGR 3Y CAGR 5Y CAGR 10Y
Mesoblast Ltd
ASX:MSB
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immutep Ltd
ASX:IMM
Cash Interest Paid
-AU$20.5k
CAGR 3-Years
-16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Cash Interest Paid
$432m
CAGR 3-Years
39%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Telix Pharmaceuticals Ltd
ASX:TLX
Cash Interest Paid
-AU$785k
CAGR 3-Years
-60%
CAGR 5-Years
-115%
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Cash Interest Paid
-AU$49.4k
CAGR 3-Years
-8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Mesoblast Ltd
Glance View

Market Cap
2.9B AUD
Industry
Biotechnology

Mesoblast Ltd., a biotechnology company based in Australia, is navigating the frontier of regenerative medicine with its innovative approach to cell therapy. Founded in 2004, Mesoblast has carved a niche for itself by concentrating on the development and commercialization of allogeneic cellular medicines derived from mesenchymal lineage adult stem cells. These stem cells are pivotal in regenerative therapy due to their remarkable ability to differentiate, reduce inflammation, and promote tissue repair. Mesoblast harnesses this potential to address critical medical conditions, including cardiovascular diseases, spine diseases, immune-mediated diseases, and some rare pediatric conditions. By developing proprietary technology, the company aims to produce off-the-shelf therapies that can be readily available to patients, avoiding the complexities and delays often associated with personalized cellular therapies. The company’s revenue model hinges on the development of its extensive pipeline of products, with an eye towards capturing significant market opportunities across multiple therapeutic areas. Revenues are primarily anticipated from three avenues: collaborations with major pharmaceutical companies, licensing agreements, and, eventually, product sales upon regulatory approval. Mesoblast's strategic partnerships often involve substantial upfront payments, milestone payments, and royalties on the sale of licensed products. For instance, collaborations with giants like Grunenthal in Europe have fortified its research and funding capabilities. Meanwhile, Mesoblast is also committed to expanding its product commercialization capabilities to strategically manage its transition from a research-centered entity to a biopharmaceutical pioneer with marketed therapies. This dual-focused strategy aspires to deliver shareholder value while advancing the horizons of medical treatment.

MSB Intrinsic Value
6.84 AUD
Undervaluation 63%
Intrinsic Value
Price

See Also

Back to Top